The Fixed-dose Combination Drug for Secondary Cardiovascular Prevention project: Improving equitable access and adherence to secondary cardiovascular prevention with a fixed-dose combination drug. Study design and objectives
In spite of advances in prevention and treatment, the burden of cardiovascular diseases is increasing. A fixed-dose combination (FDC) pill, or “polypill,” composed of evidence-based drugs has been proposed as a means of improving cardiovascular prevention by reducing cost and increasing patient adhe...
Gespeichert in:
| Veröffentlicht in: | The American heart journal 2011-11, Vol.162 (5), p.811-817.e1 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 817.e1 |
|---|---|
| container_issue | 5 |
| container_start_page | 811 |
| container_title | The American heart journal |
| container_volume | 162 |
| creator | Sanz, Ginés, MD, PhD Fuster, Valentin, MD, PhD Guzmán, Luis, MD Guglietta, Antonio, MD, PhD Arnáiz, Joan Albert, MD, PhD Martínez, Felipe, MD Sarria, Antonio, MD, PhD Roncaglioni, Maria Carla, Biol Sci Dr Taubert, Kathryn, PhD |
| description | In spite of advances in prevention and treatment, the burden of cardiovascular diseases is increasing. A fixed-dose combination (FDC) pill, or “polypill,” composed of evidence-based drugs has been proposed as a means of improving cardiovascular prevention by reducing cost and increasing patient adherence to treatment. The aim of the FOCUS project, funded by the 7th Framework Programme of the European Commission, is to characterize the factors that underlie inadequate secondary prevention and to test a new FDC. To achieve these goals, a 9-member consortium has been constituted, including institutions from Argentina, France, Italy, Spain, and Switzerland. FOCUS Phase-1 will examine factors potentially related to lack of adequate secondary prevention in 4,000 post–myocardial infarction (MI) patients and analyze the relationship between these factors and patient treatment adherence. Primary end points will be (1) the percentage of patients receiving aspirin, angiotensin-converting enzyme inhibitors, and statins and (2) adherence to treatment measured by the Morisky-Green test. FOCUS Phase-2 is a randomized trial that will compare adherence to treatment in 1,340 post–myocardial infarction patients either receiving an FDC comprising aspirin (100 mg), ramipril (2.5, 5, or 10 mg), and simvastatin (40 mg) or receiving the same 3 drugs separately. |
| doi_str_mv | 10.1016/j.ahj.2011.08.012 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_905669464</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0002870311006296</els_id><sourcerecordid>905669464</sourcerecordid><originalsourceid>FETCH-LOGICAL-c465t-f4a3d62923018ff36d024aa7235f260afbd80607525ca5f7524b6a9e39c4d7383</originalsourceid><addsrcrecordid>eNp9ktFu0zAUhiMEYt3gAbhBlhDaVYLtJE7MJCRUGEyaBFLHteXYJ61Dand2Uujb8ig4a1lhF1zZlr7z-z_nP0nyguCMYMLedJlcdRnFhGS4zjChj5IZwbxKWVUUj5MZxpimdYXzk-Q0hC4-Ga3Z0-SEUsxzwstZ8utmBejS_ASdahcAzd26MVYOxln0wY9L1DqPFqCc1dLv0Fx6bdxWBjX20qOvHrZg7-CNdx2o4S26Wsfr1tglgtvRDLLpAUmlIAQkrUZSr8CDVYAGh8K9sPpXeHMU_mGGFZKoPXpUf3nU0WOGFsOod0hDMEt794trJjNmC-FZ8qSVfYDnh_Ms-Xb58Wb-Ob3-8ulq_v46VQUrh7QtZK4Z5TTHpG7bnGlMCykrmpctZVi2ja4xw1VJSyXLNp5FwySHnKtCV3mdnyXne93Y_e0IYRBrExT0vbTgxiA4LhnjBSsi-eoB2bnR22hOkJIUdckZJ5Eie0p5F4KHVmy8WcdRCYLFlL7oRExfTOkLXIuYfqx5eVAemzXo-4o_cUfg9QGIg5Z966VVJhy52B2JfUfuYs9BnNjWgBdBmSk0bXycq9DO_NfGuwfVqjfWxA-_ww7CsVsRqMBiMa3ptKWETAvKWf4b3e_mKA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1514859691</pqid></control><display><type>article</type><title>The Fixed-dose Combination Drug for Secondary Cardiovascular Prevention project: Improving equitable access and adherence to secondary cardiovascular prevention with a fixed-dose combination drug. Study design and objectives</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><source>ProQuest Central UK/Ireland</source><creator>Sanz, Ginés, MD, PhD ; Fuster, Valentin, MD, PhD ; Guzmán, Luis, MD ; Guglietta, Antonio, MD, PhD ; Arnáiz, Joan Albert, MD, PhD ; Martínez, Felipe, MD ; Sarria, Antonio, MD, PhD ; Roncaglioni, Maria Carla, Biol Sci Dr ; Taubert, Kathryn, PhD</creator><creatorcontrib>Sanz, Ginés, MD, PhD ; Fuster, Valentin, MD, PhD ; Guzmán, Luis, MD ; Guglietta, Antonio, MD, PhD ; Arnáiz, Joan Albert, MD, PhD ; Martínez, Felipe, MD ; Sarria, Antonio, MD, PhD ; Roncaglioni, Maria Carla, Biol Sci Dr ; Taubert, Kathryn, PhD</creatorcontrib><description>In spite of advances in prevention and treatment, the burden of cardiovascular diseases is increasing. A fixed-dose combination (FDC) pill, or “polypill,” composed of evidence-based drugs has been proposed as a means of improving cardiovascular prevention by reducing cost and increasing patient adherence to treatment. The aim of the FOCUS project, funded by the 7th Framework Programme of the European Commission, is to characterize the factors that underlie inadequate secondary prevention and to test a new FDC. To achieve these goals, a 9-member consortium has been constituted, including institutions from Argentina, France, Italy, Spain, and Switzerland. FOCUS Phase-1 will examine factors potentially related to lack of adequate secondary prevention in 4,000 post–myocardial infarction (MI) patients and analyze the relationship between these factors and patient treatment adherence. Primary end points will be (1) the percentage of patients receiving aspirin, angiotensin-converting enzyme inhibitors, and statins and (2) adherence to treatment measured by the Morisky-Green test. FOCUS Phase-2 is a randomized trial that will compare adherence to treatment in 1,340 post–myocardial infarction patients either receiving an FDC comprising aspirin (100 mg), ramipril (2.5, 5, or 10 mg), and simvastatin (40 mg) or receiving the same 3 drugs separately.</description><identifier>ISSN: 0002-8703</identifier><identifier>EISSN: 1097-6744</identifier><identifier>DOI: 10.1016/j.ahj.2011.08.012</identifier><identifier>PMID: 22093195</identifier><identifier>CODEN: AHJOA2</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Angiotensin-Converting Enzyme Inhibitors - administration & dosage ; Argentina ; Aspirin ; Aspirin - administration & dosage ; Biological and medical sciences ; Blood pressure ; Cardiology. Vascular system ; Cardiovascular ; Cardiovascular disease ; Cardiovascular Diseases - prevention & control ; Disease prevention ; Drug Combinations ; Drug dosages ; Drug therapy ; Europe ; GDP ; Gross Domestic Product ; Heart attacks ; Heart failure ; Hospital costs ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage ; Hypotheses ; Lung diseases ; Medical sciences ; Medication Adherence ; Mortality ; Objectives ; Patient Selection ; Pharmaceuticals ; Platelet Aggregation Inhibitors - administration & dosage ; Population ; Prescription drugs ; Questionnaires ; Research Design ; Risk factors ; Socioeconomic factors ; Variables</subject><ispartof>The American heart journal, 2011-11, Vol.162 (5), p.811-817.e1</ispartof><rights>Mosby, Inc.</rights><rights>2011 Mosby, Inc.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2011 Mosby, Inc. All rights reserved.</rights><rights>Copyright Elsevier Limited Nov 2011</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c465t-f4a3d62923018ff36d024aa7235f260afbd80607525ca5f7524b6a9e39c4d7383</citedby><cites>FETCH-LOGICAL-c465t-f4a3d62923018ff36d024aa7235f260afbd80607525ca5f7524b6a9e39c4d7383</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1514859691?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>315,782,786,3552,27931,27932,46002,64392,64394,64396,72476</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25251024$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22093195$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sanz, Ginés, MD, PhD</creatorcontrib><creatorcontrib>Fuster, Valentin, MD, PhD</creatorcontrib><creatorcontrib>Guzmán, Luis, MD</creatorcontrib><creatorcontrib>Guglietta, Antonio, MD, PhD</creatorcontrib><creatorcontrib>Arnáiz, Joan Albert, MD, PhD</creatorcontrib><creatorcontrib>Martínez, Felipe, MD</creatorcontrib><creatorcontrib>Sarria, Antonio, MD, PhD</creatorcontrib><creatorcontrib>Roncaglioni, Maria Carla, Biol Sci Dr</creatorcontrib><creatorcontrib>Taubert, Kathryn, PhD</creatorcontrib><title>The Fixed-dose Combination Drug for Secondary Cardiovascular Prevention project: Improving equitable access and adherence to secondary cardiovascular prevention with a fixed-dose combination drug. Study design and objectives</title><title>The American heart journal</title><addtitle>Am Heart J</addtitle><description>In spite of advances in prevention and treatment, the burden of cardiovascular diseases is increasing. A fixed-dose combination (FDC) pill, or “polypill,” composed of evidence-based drugs has been proposed as a means of improving cardiovascular prevention by reducing cost and increasing patient adherence to treatment. The aim of the FOCUS project, funded by the 7th Framework Programme of the European Commission, is to characterize the factors that underlie inadequate secondary prevention and to test a new FDC. To achieve these goals, a 9-member consortium has been constituted, including institutions from Argentina, France, Italy, Spain, and Switzerland. FOCUS Phase-1 will examine factors potentially related to lack of adequate secondary prevention in 4,000 post–myocardial infarction (MI) patients and analyze the relationship between these factors and patient treatment adherence. Primary end points will be (1) the percentage of patients receiving aspirin, angiotensin-converting enzyme inhibitors, and statins and (2) adherence to treatment measured by the Morisky-Green test. FOCUS Phase-2 is a randomized trial that will compare adherence to treatment in 1,340 post–myocardial infarction patients either receiving an FDC comprising aspirin (100 mg), ramipril (2.5, 5, or 10 mg), and simvastatin (40 mg) or receiving the same 3 drugs separately.</description><subject>Angiotensin-Converting Enzyme Inhibitors - administration & dosage</subject><subject>Argentina</subject><subject>Aspirin</subject><subject>Aspirin - administration & dosage</subject><subject>Biological and medical sciences</subject><subject>Blood pressure</subject><subject>Cardiology. Vascular system</subject><subject>Cardiovascular</subject><subject>Cardiovascular disease</subject><subject>Cardiovascular Diseases - prevention & control</subject><subject>Disease prevention</subject><subject>Drug Combinations</subject><subject>Drug dosages</subject><subject>Drug therapy</subject><subject>Europe</subject><subject>GDP</subject><subject>Gross Domestic Product</subject><subject>Heart attacks</subject><subject>Heart failure</subject><subject>Hospital costs</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage</subject><subject>Hypotheses</subject><subject>Lung diseases</subject><subject>Medical sciences</subject><subject>Medication Adherence</subject><subject>Mortality</subject><subject>Objectives</subject><subject>Patient Selection</subject><subject>Pharmaceuticals</subject><subject>Platelet Aggregation Inhibitors - administration & dosage</subject><subject>Population</subject><subject>Prescription drugs</subject><subject>Questionnaires</subject><subject>Research Design</subject><subject>Risk factors</subject><subject>Socioeconomic factors</subject><subject>Variables</subject><issn>0002-8703</issn><issn>1097-6744</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9ktFu0zAUhiMEYt3gAbhBlhDaVYLtJE7MJCRUGEyaBFLHteXYJ61Dand2Uujb8ig4a1lhF1zZlr7z-z_nP0nyguCMYMLedJlcdRnFhGS4zjChj5IZwbxKWVUUj5MZxpimdYXzk-Q0hC4-Ga3Z0-SEUsxzwstZ8utmBejS_ASdahcAzd26MVYOxln0wY9L1DqPFqCc1dLv0Fx6bdxWBjX20qOvHrZg7-CNdx2o4S26Wsfr1tglgtvRDLLpAUmlIAQkrUZSr8CDVYAGh8K9sPpXeHMU_mGGFZKoPXpUf3nU0WOGFsOod0hDMEt794trJjNmC-FZ8qSVfYDnh_Ms-Xb58Wb-Ob3-8ulq_v46VQUrh7QtZK4Z5TTHpG7bnGlMCykrmpctZVi2ja4xw1VJSyXLNp5FwySHnKtCV3mdnyXne93Y_e0IYRBrExT0vbTgxiA4LhnjBSsi-eoB2bnR22hOkJIUdckZJ5Eie0p5F4KHVmy8WcdRCYLFlL7oRExfTOkLXIuYfqx5eVAemzXo-4o_cUfg9QGIg5Z966VVJhy52B2JfUfuYs9BnNjWgBdBmSk0bXycq9DO_NfGuwfVqjfWxA-_ww7CsVsRqMBiMa3ptKWETAvKWf4b3e_mKA</recordid><startdate>20111101</startdate><enddate>20111101</enddate><creator>Sanz, Ginés, MD, PhD</creator><creator>Fuster, Valentin, MD, PhD</creator><creator>Guzmán, Luis, MD</creator><creator>Guglietta, Antonio, MD, PhD</creator><creator>Arnáiz, Joan Albert, MD, PhD</creator><creator>Martínez, Felipe, MD</creator><creator>Sarria, Antonio, MD, PhD</creator><creator>Roncaglioni, Maria Carla, Biol Sci Dr</creator><creator>Taubert, Kathryn, PhD</creator><general>Elsevier Inc</general><general>Mosby</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7RV</scope><scope>7TS</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20111101</creationdate><title>The Fixed-dose Combination Drug for Secondary Cardiovascular Prevention project: Improving equitable access and adherence to secondary cardiovascular prevention with a fixed-dose combination drug. Study design and objectives</title><author>Sanz, Ginés, MD, PhD ; Fuster, Valentin, MD, PhD ; Guzmán, Luis, MD ; Guglietta, Antonio, MD, PhD ; Arnáiz, Joan Albert, MD, PhD ; Martínez, Felipe, MD ; Sarria, Antonio, MD, PhD ; Roncaglioni, Maria Carla, Biol Sci Dr ; Taubert, Kathryn, PhD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c465t-f4a3d62923018ff36d024aa7235f260afbd80607525ca5f7524b6a9e39c4d7383</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Angiotensin-Converting Enzyme Inhibitors - administration & dosage</topic><topic>Argentina</topic><topic>Aspirin</topic><topic>Aspirin - administration & dosage</topic><topic>Biological and medical sciences</topic><topic>Blood pressure</topic><topic>Cardiology. Vascular system</topic><topic>Cardiovascular</topic><topic>Cardiovascular disease</topic><topic>Cardiovascular Diseases - prevention & control</topic><topic>Disease prevention</topic><topic>Drug Combinations</topic><topic>Drug dosages</topic><topic>Drug therapy</topic><topic>Europe</topic><topic>GDP</topic><topic>Gross Domestic Product</topic><topic>Heart attacks</topic><topic>Heart failure</topic><topic>Hospital costs</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage</topic><topic>Hypotheses</topic><topic>Lung diseases</topic><topic>Medical sciences</topic><topic>Medication Adherence</topic><topic>Mortality</topic><topic>Objectives</topic><topic>Patient Selection</topic><topic>Pharmaceuticals</topic><topic>Platelet Aggregation Inhibitors - administration & dosage</topic><topic>Population</topic><topic>Prescription drugs</topic><topic>Questionnaires</topic><topic>Research Design</topic><topic>Risk factors</topic><topic>Socioeconomic factors</topic><topic>Variables</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sanz, Ginés, MD, PhD</creatorcontrib><creatorcontrib>Fuster, Valentin, MD, PhD</creatorcontrib><creatorcontrib>Guzmán, Luis, MD</creatorcontrib><creatorcontrib>Guglietta, Antonio, MD, PhD</creatorcontrib><creatorcontrib>Arnáiz, Joan Albert, MD, PhD</creatorcontrib><creatorcontrib>Martínez, Felipe, MD</creatorcontrib><creatorcontrib>Sarria, Antonio, MD, PhD</creatorcontrib><creatorcontrib>Roncaglioni, Maria Carla, Biol Sci Dr</creatorcontrib><creatorcontrib>Taubert, Kathryn, PhD</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Physical Education Index</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The American heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sanz, Ginés, MD, PhD</au><au>Fuster, Valentin, MD, PhD</au><au>Guzmán, Luis, MD</au><au>Guglietta, Antonio, MD, PhD</au><au>Arnáiz, Joan Albert, MD, PhD</au><au>Martínez, Felipe, MD</au><au>Sarria, Antonio, MD, PhD</au><au>Roncaglioni, Maria Carla, Biol Sci Dr</au><au>Taubert, Kathryn, PhD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Fixed-dose Combination Drug for Secondary Cardiovascular Prevention project: Improving equitable access and adherence to secondary cardiovascular prevention with a fixed-dose combination drug. Study design and objectives</atitle><jtitle>The American heart journal</jtitle><addtitle>Am Heart J</addtitle><date>2011-11-01</date><risdate>2011</risdate><volume>162</volume><issue>5</issue><spage>811</spage><epage>817.e1</epage><pages>811-817.e1</pages><issn>0002-8703</issn><eissn>1097-6744</eissn><coden>AHJOA2</coden><abstract>In spite of advances in prevention and treatment, the burden of cardiovascular diseases is increasing. A fixed-dose combination (FDC) pill, or “polypill,” composed of evidence-based drugs has been proposed as a means of improving cardiovascular prevention by reducing cost and increasing patient adherence to treatment. The aim of the FOCUS project, funded by the 7th Framework Programme of the European Commission, is to characterize the factors that underlie inadequate secondary prevention and to test a new FDC. To achieve these goals, a 9-member consortium has been constituted, including institutions from Argentina, France, Italy, Spain, and Switzerland. FOCUS Phase-1 will examine factors potentially related to lack of adequate secondary prevention in 4,000 post–myocardial infarction (MI) patients and analyze the relationship between these factors and patient treatment adherence. Primary end points will be (1) the percentage of patients receiving aspirin, angiotensin-converting enzyme inhibitors, and statins and (2) adherence to treatment measured by the Morisky-Green test. FOCUS Phase-2 is a randomized trial that will compare adherence to treatment in 1,340 post–myocardial infarction patients either receiving an FDC comprising aspirin (100 mg), ramipril (2.5, 5, or 10 mg), and simvastatin (40 mg) or receiving the same 3 drugs separately.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>22093195</pmid><doi>10.1016/j.ahj.2011.08.012</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-8703 |
| ispartof | The American heart journal, 2011-11, Vol.162 (5), p.811-817.e1 |
| issn | 0002-8703 1097-6744 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_905669464 |
| source | MEDLINE; Access via ScienceDirect (Elsevier); ProQuest Central UK/Ireland |
| subjects | Angiotensin-Converting Enzyme Inhibitors - administration & dosage Argentina Aspirin Aspirin - administration & dosage Biological and medical sciences Blood pressure Cardiology. Vascular system Cardiovascular Cardiovascular disease Cardiovascular Diseases - prevention & control Disease prevention Drug Combinations Drug dosages Drug therapy Europe GDP Gross Domestic Product Heart attacks Heart failure Hospital costs Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage Hypotheses Lung diseases Medical sciences Medication Adherence Mortality Objectives Patient Selection Pharmaceuticals Platelet Aggregation Inhibitors - administration & dosage Population Prescription drugs Questionnaires Research Design Risk factors Socioeconomic factors Variables |
| title | The Fixed-dose Combination Drug for Secondary Cardiovascular Prevention project: Improving equitable access and adherence to secondary cardiovascular prevention with a fixed-dose combination drug. Study design and objectives |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T08%3A25%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Fixed-dose%20Combination%20Drug%20for%20Secondary%20Cardiovascular%20Prevention%20project:%20Improving%20equitable%20access%20and%20adherence%20to%20secondary%20cardiovascular%20prevention%20with%20a%20fixed-dose%20combination%20drug.%20Study%20design%20and%20objectives&rft.jtitle=The%20American%20heart%20journal&rft.au=Sanz,%20Gin%C3%A9s,%20MD,%20PhD&rft.date=2011-11-01&rft.volume=162&rft.issue=5&rft.spage=811&rft.epage=817.e1&rft.pages=811-817.e1&rft.issn=0002-8703&rft.eissn=1097-6744&rft.coden=AHJOA2&rft_id=info:doi/10.1016/j.ahj.2011.08.012&rft_dat=%3Cproquest_cross%3E905669464%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1514859691&rft_id=info:pmid/22093195&rft_els_id=1_s2_0_S0002870311006296&rfr_iscdi=true |